Search Results for “diagnostic” – Page 51 – media

Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says

The maker of the mpox vaccine is looking at ways to dramatically scale up its production capacity to prepare for a potential threat from smallpox. Bavarian Nordic CEO Paul Chaplin said the rapid spread of mpox last year was a wake-up call for the company, which is based in Denmark. “If it wasn’t mpox but it was smallpox, we are completely at the wrong scale,” Chaplin told CNBC in an interview. “We’re looking at ways we can dramatically change the way we manufacture to increase our scale,” he said. Mpox is in the same virus family as smallpox. Bavarian Nordic’s Jynneos vaccine is approved by the U.S. Food and Drug Administration to protect against both pathogens. Previously known as monkeypox, the World Health Organization changed the name to mpox last year to reduce stigma. Bavarian Nordic plans to simplify its production process so ...
- Source: drugdu
- 109
- May 5, 2023
Pfizer Acquires COVID-Flu Test Developer Lucira Health for USD 36.4 Million

By LabMedica International staff writers Pfizer Inc. (New York, NY, USA) has acquired Lucira Health, Inc. (Emeryville, CA, USA) for USD 36.4 million in a bankruptcy auction. Lucira filed for bankruptcy in February 2023, just two days before receiving FDA Emergency Use Authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test capable of differentiating and detecting influenza A and B. The COVID-19 & Flu Home Test is a single-use at-home test kit that delivers results from self-collected nasal swab samples in about 30 minutes. Lucira had previously received the first FDA EUA for an at-home rapid self-test, the Lucira COVID-19 All-in-One Test Kit, in November 2020, and the company announced in April 2021 that it had secured OTC EUA for its Lucira Check It test kit for SARS-CoV-2. The company’s tests use a handheld battery-powered real-time testing instrument with nasal swab samples and loop-mediated isothermal amplification to provide ...
- Source: drugdu
- 122
- May 5, 2023
Excessive digital technology use is associated with reduced sleep quality regardless of environmental and genetic factors, study finds

In a recent study published in the SLEEP Journal, researchers explored the association between poor sleep and the excessive use of digital technology among adolescents after adjusting for familial factors and examining the influence of environmental and genetic factors on the association. Background Although many studies have reported that excessive use of digital technology among adolescents and young adults is linked to lower sleep quality, recent research indicates that in studies that used relevant control groups, the association was weaker or non-significant. This implied that a third unexplored factor, such as environmental or genetic influences, could be the underlying reason for these observed associations. Factors related to parental control and lack of boundaries resulting in inconsistent bedtimes and excessive use of technology could be impacting the quality of sleep. Digital technology is thought to impact sleep quality in various ways. Hyperarousal and the requirement to constantly ...
- Source: drugdu
- 134
- May 3, 2023
Quest to Reach Another Segment in Liquid Biopsy with New M&A

Omar Ford Quest Diagnostics is diving into a quickly growing segment of liquid biopsy with its latest M&A prospect. The Secaucus, NJ-based company announced a definitive agreement to acquire Haystack Oncology in an all-cash equity transaction. Quest will pay $300 million in cash at closing and Haystack has the potential to obtain up to an additional $150 million in performance milestones. If the deal were to close, then Quest would inherit Baltimore, MD – based Haystack’s minimal residual disease testing technology. MRD testing is a specific category of liquid biopsy that identifies circulating tumor DNA (ctDNA) in the bloodstream of patients following surgery and treatment for cancer. In a prospective, multi-institution study published in the New England Journal of Medicine in June 2022, an earlier version of the Haystack technology demonstrated the ability to better identify patients with residual disease for adjuvant chemotherapy after surgery for stage II colon cancer, thereby reducing ...
- Source: drugdu
- 139
- May 1, 2023
Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition

Quest Diagnostics is boosting its capabilities in cancer, paying $300 million to acquire a Johns Hopkins University spinout whose technology identifies cancer cells in order to guide treatment decisions. The Secaucus, New Jersey-based diagnostics giant on Thursday announced the cash acquisition of Haystack Oncology. The Baltimore-based startup is part of a growing area in cancer testing called liquid biopsies, tests that detect cancer by finding circulating tumor DNA in a patient’s blood sample. Grail and Guardant Health are among the companies that market tests that detect early signs of cancer, enabling clinicians to intervene sooner. Haystack’s focus is minimal residual disease—detecting cancer cells that remain following initial treatment with surgery or a drug. Test results help clinicians assess how well the initial treatment worked and whether additional treatment, called an adjuvant, is necessary to kill any lingering cancer cells. That’s important because additional treatment, often a chemotherapy, introduces a wide ...
- Source: drugdu
- 176
- April 29, 2023
AI breakthrough in detecting leading cause of childhood blindness

The team developed a deep learning AI model that can identify which at-risk infants have ROP that may lead to blindness if left untreated, and they hope their technique could improve access to screening in the many areas with limited neonatal services and few trained ophthalmologists. The study, by an international team of scientists and clinicians in the UK, Brazil, Egypt and the US, supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, is published in The Lancet Digital Health. Lead author Dr. Konstantinos Balaskas (Director, Moorfields Ophthalmic Reading Centre & Clinical AI Lab, Moorfields Eye Hospital and Associate Professor, UCL Institute of Ophthalmology) said, “Retinopathy of prematurity is becoming increasingly common as survival rates of premature babies improve across the globe, and it is now the leading cause of childhood blindness in ...
- Source: drugdu
- 136
- April 29, 2023
New tool charts differentiation landscape of acute myeloid leukemia

by Center for Genomic Regulation Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify. The findings, published today in the journal Cell Stem Cell, pave the way for the development of new techniques to predict whether patients will respond to chemotherapy. AML is a type of cancer characterized by the rapid growth and accumulation of abnormal white blood cells. It is thought to develop when blood progenitor cells, which normally turn into all other types of blood cells, fail to mature properly and become abnormal. In this process, blood stem cells carry a special importance because they give rise to progenitor cells and are thought to be the cell type in which leukemic mutations occur. Leukemic stem cells are thought ...
- Source: drugdu
- 124
- April 26, 2023
New machine-learning method predicts body clock timing to improve sleep and health decisions

A new machine-learning method could help us gauge the time of our internal body clock, helping us all make better health decisions, including when and how long to sleep. The research, which has been conducted by the University of Surrey and the University of Groningen, used a machine learning program to analyze metabolites in blood to predict the time of our internal circadian timing system. The study is published in the journal Proceedings of the National Academy of Sciences. To date the standard method to determine the timing of the circadian system is to measure the timing of our natural melatonin rhythm, specifically when we start producing melatonin, known as dim light melatonin onset (DLMO). Professor Debra Skene, co-author of the study from the University of Surrey, said, “After taking two blood samples from our participants, our method was able to predict the DLMO of individuals with an accuracy comparable ...
- Source: drugdu
- 125
- April 26, 2023
Is there a link between psychiatric and reproductive system disorders in women?

In a recent study published in the journal JAMA Network Open, researchers performed a meta-analysis to assess the co-occurrence of reproductive and psychiatric disorders among women. Disorders associated with the female mental well-being and reproductive tract commonly co-exist; however, the precise cause of the co-occurrence is not clear. Probable causes include non-intrinsic or external-type factors that interfere with the reproductive system, including psychotropic-type medications, psychosocial causes like reproductive disorders impacting relationships and life quality, and stress affecting reproductive functions and the menstrual cycle. Moreover, the overlap could originate from genetic causes. About the study In the present meta-analysis, researchers determined the association between female reproductive and psychiatric functions. The PubMed database was searched for observational-type and peer-reviewed studies (population-level cross-sectional and case-control studies), including reproductive-age females aged between 13.0 and 55.0 years, published from January 1980 to December 2019, evaluating the prevalence of mental health disorders among ...
- Source: drugdu
- 112
- April 20, 2023
Caris Life Sciences and Flare to collaborate for oncology pipeline advancement

Caris Life Sciences and Flare Therapeutics have announced a partnership to advance the precision oncology pipeline of the latter into clinical trials. The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare. It will use the comprehensive molecular tissue and liquid profiling services of Caris including whole transcriptome sequencing and whole exome sequencing for participants in Flare’s clinical trials. Additionally, the partnership will apply Caris’ data and analytics tools to strengthen future enrolment programme for trials and companion diagnostics capabilities. Flare Therapeutics chief development officer Michaela Bowden said: “We understand the importance of shaping translational insights early on as a major area of focus to help ensure efficient drug development at scale and clinical trial preparedness. “With access to Caris’ robust clinico-genomic real-world data, comprehensive molecular profiling and ...
- Source: drugdu
- 171
- April 17, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.